IS20

Overview

IS20 is a Prokineticin receptor 1 (PKR1) agonist. IS20 diminishes Doxorubicin ( HY-15142A ) mediated apoptosis and ROS production by activating Akt or MAPK pathways. IS20 protects the heart against Doxorubicin -induced cardiovascular toxicity and improves the survival rate and cardiac function in mouse models. IS20 does not alter the cytotoxicity and antitumor activity of acute DOX treatment in breast cancer cells and MDA-MB-231 xenograft mouse models. IS20 can be used for cancers research.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Breast Cancer | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > Akt | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > G Protein-coupled Receptor Kinase (GRK)

Product Information

• Catalog No.: HY-125807
• CAS No.: 324561-95-7
• Molecular Formula: C23H21N3O3
• Molecular Weight: 387.43
• Purity: 99.85%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (6.45 mM); Clear solution
• Availability: In-stock

Source

Original product source